tirzepatide cause death linked to lower risk for death, adverse CV and kidney outcomes vs. GLP-1s Tirzepatide Associated with Lower Risk

Cardiometabolic Risk: Ongoing research interest in blood pressure, lipids, inflammatory markers, and other cardiometabolic endpoints

Research supports spreading protein intake across three to four meals or feeding events, with each meal containing a sufficient dose (typically 2540 grams of high-quality protein) to maximally stimulate MPS. GLP-1 users face a practical problem: appetite suppression often compresses eating windows and reduces meal size, making it difficult to hit adequate per-meal protein doses even when overall daily targets are attempted

According to FDA labeling, no dose adjustment is required in patients with renal impairment, including those with end-stage renal disease (ESRD)

Neuroendocrine control of sleep